• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球癌症免疫治疗中 B7-H3 的研究趋势:文献计量分析(2012-2022 年)。

Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022).

机构信息

Department of Oncology, Qingdao Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.

出版信息

Hum Vaccin Immunother. 2023 Aug 1;19(2):2246498. doi: 10.1080/21645515.2023.2246498.

DOI:10.1080/21645515.2023.2246498
PMID:37635349
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10464541/
Abstract

Immunotherapy has revolutionized cancer treatment. B7-H3 is a promising target for cancer immunotherapy (CI). The present study aimed to utilize bibliometric methods to assess the current research status and explore future trends in the use of B7-H3 for CI. We collected publications related to B7-H3/CI from the Clarivate Web of Science Core Collection database. VOSviewer, Microsoft Excel, the bibliometrix R package, and an online platform were used to conduct qualitative and visualized analyses of the literature. A total of 555 papers were analyzed, revealing a significant increase in annual publications since 2018. The most productive countries were China and the USA, and the leading institutions were Soochow University and Sichuan University. Zang and Ferrone were the most popular authors. Among the journals, had the highest number of papers, whereas was the most influential. Historical citation analysis reveals the development of B7-H3/CI. Top-cited papers and keyword analyses were performed to highlight current hotspots in the domain. Using cluster analysis, we classified all keywords into four clusters: "immunotherapy," "co-stimulatory molecule," "B7 family," and "PD-L1." Finally, Trends analysis suggested that future research might focus on "chimeric antigen receptor," "pathways," and "targeting B7-H3." This is the first bibliometric crosstalk analysis between B7-H3 and CI. Our study illustrates that the topic of B7-H3/CI is very popular and has great clinical implications and that the number of correlative publications will continue to increase. B7-H3-based CI may lead to new research trends.

摘要

免疫疗法已经彻底改变了癌症治疗。B7-H3 是癌症免疫治疗 (CI) 的一个有前途的靶点。本研究旨在利用文献计量学方法评估 B7-H3 用于 CI 的当前研究现状并探索未来趋势。我们从科睿唯安 Web of Science 核心合集数据库中收集了与 B7-H3/CI 相关的出版物。使用 VOSviewer、Microsoft Excel、bibliometrix R 包和在线平台对文献进行定性和可视化分析。共分析了 555 篇论文,显示自 2018 年以来年度出版物数量显著增加。最具生产力的国家是中国和美国,领先的机构是苏州大学和四川大学。Zang 和 Ferrone 是最受欢迎的作者。在期刊中, 发表的论文数量最多,而 是最有影响力的期刊。历史引文分析揭示了 B7-H3/CI 的发展。对高被引论文和关键词分析突出了该领域的当前热点。使用聚类分析,我们将所有关键词分为四个聚类:“免疫疗法”、“共刺激分子”、“B7 家族”和“PD-L1”。最后,趋势分析表明,未来的研究可能集中在“嵌合抗原受体”、“途径”和“靶向 B7-H3”上。这是 B7-H3 和 CI 之间的首次文献计量交叉分析。我们的研究表明,B7-H3/CI 主题非常热门,具有重要的临床意义,相关出版物的数量将继续增加。基于 B7-H3 的 CI 可能会带来新的研究趋势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/8b7db6d4bde1/KHVI_A_2246498_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/323c7aedeff3/KHVI_A_2246498_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/74a682657d1b/KHVI_A_2246498_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/da9f4e8f2206/KHVI_A_2246498_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/995a96e390ac/KHVI_A_2246498_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/b66b44668157/KHVI_A_2246498_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/cb6cb4146794/KHVI_A_2246498_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/8b7db6d4bde1/KHVI_A_2246498_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/323c7aedeff3/KHVI_A_2246498_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/74a682657d1b/KHVI_A_2246498_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/da9f4e8f2206/KHVI_A_2246498_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/995a96e390ac/KHVI_A_2246498_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/b66b44668157/KHVI_A_2246498_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/cb6cb4146794/KHVI_A_2246498_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/8b7db6d4bde1/KHVI_A_2246498_F0007_OC.jpg

相似文献

1
Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022).全球癌症免疫治疗中 B7-H3 的研究趋势:文献计量分析(2012-2022 年)。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2246498. doi: 10.1080/21645515.2023.2246498.
2
Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021).全球关于肠道微生物群与癌症免疫治疗关联的研究趋势:文献计量分析(2012-2021 年)。
Front Immunol. 2022 Aug 24;13:952546. doi: 10.3389/fimmu.2022.952546. eCollection 2022.
3
Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study.基于文献计量学的前列腺癌免疫治疗知识图谱及研究热点分析
Front Immunol. 2022 Oct 27;13:1014981. doi: 10.3389/fimmu.2022.1014981. eCollection 2022.
4
Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study.全球肿瘤免疫微环境(TIME)相关出版物的生产力和研究趋势:一项文献计量学研究。
Eur J Med Res. 2023 Jul 10;28(1):229. doi: 10.1186/s40001-023-01195-3.
5
Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021.2001 年至 2021 年基于嵌合抗原受体的免疫疗法治疗癌症的文献计量学分析。
Front Immunol. 2022 Mar 30;13:822004. doi: 10.3389/fimmu.2022.822004. eCollection 2022.
6
Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis.全球胶质母细胞瘤免疫治疗研究趋势:全面可视化和文献计量分析。
Front Endocrinol (Lausanne). 2023 Oct 5;14:1273634. doi: 10.3389/fendo.2023.1273634. eCollection 2023.
7
Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis.食管癌抗PD-1/PD-L1免疫治疗的研究趋势:一项文献计量分析
Front Oncol. 2022 Nov 17;12:983892. doi: 10.3389/fonc.2022.983892. eCollection 2022.
8
Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study.溶瘤病毒治疗中枢神经系统肿瘤的研究热点和趋势:文献计量学研究。
Front Immunol. 2022 Sep 6;13:975695. doi: 10.3389/fimmu.2022.975695. eCollection 2022.
9
Research Trends in the Application of Artificial Intelligence in Oncology: A Bibliometric and Network Visualization Study.人工智能在肿瘤学应用中的研究趋势:文献计量学和网络可视化研究。
Front Biosci (Landmark Ed). 2022 Aug 31;27(9):254. doi: 10.31083/j.fbl2709254.
10
Bibliometric and visualized analysis of the top-100 highly cited articles on immunotherapy for endometrial cancer.免疫治疗子宫内膜癌的前 100 篇高被引文献的计量学和可视化分析。
Medicine (Baltimore). 2023 Jul 7;102(27):e34228. doi: 10.1097/MD.0000000000034228.

引用本文的文献

1
Radiomic features based on pyradiomics predict CD276 expression associated with breast cancer prognosis.基于pyradiomics的影像组学特征可预测与乳腺癌预后相关的CD276表达。
Heliyon. 2024 Sep 3;10(17):e37345. doi: 10.1016/j.heliyon.2024.e37345. eCollection 2024 Sep 15.
2
Current status and future directions of nanovaccine for cancer: a bibliometric analysis during 2004-2023.纳米疫苗治疗癌症的现状与未来方向:2004-2023 年的文献计量分析
Front Immunol. 2024 Jul 29;15:1423212. doi: 10.3389/fimmu.2024.1423212. eCollection 2024.

本文引用的文献

1
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.B7-H3 免疫检查点在癌症中的作用:从免疫学角度到临床免疫治疗。
J Hematol Oncol. 2022 Oct 25;15(1):153. doi: 10.1186/s13045-022-01364-7.
2
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.双 checkpoint 靶向药物恩沃利单抗联合帕博利珠单抗治疗晚期实体瘤:来自多中心 I/II 期试验的初步结果。
J Immunother Cancer. 2022 Apr;10(4). doi: 10.1136/jitc-2021-004424.
3
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.
十年后的免疫检查点抑制剂:基础研究与临床应用在癌症免疫治疗中的贡献
Immune Netw. 2022 Feb 14;22(1):e2. doi: 10.4110/in.2022.22.e2. eCollection 2022 Feb.
4
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.免疫检查点抑制剂治疗临床试验中泌尿系统癌症患者的不良反应:协作性系统评价和荟萃分析。
Eur Urol. 2022 Apr;81(4):414-425. doi: 10.1016/j.eururo.2022.01.028. Epub 2022 Jan 31.
5
Molecular basis of C-mannosylation - a structural perspective.C-甘露糖基化的分子基础——结构视角。
FEBS J. 2022 Dec;289(24):7670-7687. doi: 10.1111/febs.16265. Epub 2021 Nov 21.
6
The role of B7-H3 in tumors and its potential in clinical application.B7-H3 在肿瘤中的作用及其在临床应用中的潜力。
Int Immunopharmacol. 2021 Dec;101(Pt B):108153. doi: 10.1016/j.intimp.2021.108153. Epub 2021 Oct 19.
7
B7-H3/CD276: An Emerging Cancer Immunotherapy.B7-H3/CD276:一种新兴的癌症免疫疗法。
Front Immunol. 2021 Jul 19;12:701006. doi: 10.3389/fimmu.2021.701006. eCollection 2021.
8
FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer.FUT8 介导的 B7H3 异常 N-糖基化抑制三阴性乳腺癌的免疫应答。
Nat Commun. 2021 May 11;12(1):2672. doi: 10.1038/s41467-021-22618-x.
9
Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer.B7-H3 在人胃癌中性粒细胞中的表达、调控及临床意义。
Clin Immunol. 2021 Jun;227:108753. doi: 10.1016/j.clim.2021.108753. Epub 2021 May 1.
10
CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance.CD276 表达使鳞状细胞癌干细胞能够逃避免疫监视。
Cell Stem Cell. 2021 Sep 2;28(9):1597-1613.e7. doi: 10.1016/j.stem.2021.04.011. Epub 2021 May 3.